$NKTR
NEKTAR THERAPEUTICS Stock $nktr

$nktr Overview Financials Valuation SEC Filings Company Website

2021 Q1 Form 10-Q Financial Statement

#000090670921000008 Filed on May 07, 2021

Income Statement

Concept	2021 Q1	2020 Q1
Revenue	$23.65M	$50.57M
YoY Change	-53.24%	79.2%
Cost Of Revenue	$5.756M	$3.811M
YoY Change	51.04%	-29.94%
Gross Profit	$17.89M	$46.76M
YoY Change	-61.74%	105.26%
Gross Profit Margin	75.66%	92.46%
Selling, General & Admin	$31.70M	$26.20M
YoY Change	20.99%	4.8%
% of Gross Profit	177.18%	56.03%
Research & Development	$95.60M	$109.0M
YoY Change	-12.28%	-8.0%
% of Gross Profit	534.37%	233.07%
Depreciation & Amortization	$3.500M	$4.500M
YoY Change	-22.22%	45.16%
% of Gross Profit	19.56%	9.62%
Operating Expenses	$95.60M	$109.0M
YoY Change	-12.28%	-8.0%
Operating Profit	-$109.4M	-$133.6M
YoY Change	-18.14%	10.73%
Interest Expense	$0.00	$6.204M
YoY Change	-100.0%	18.71%
% of Operating Profit
Other Income/Expense, Net	-$13.48M	-$4.820M
YoY Change	179.73%	-504.36%
Pretax Income	-$122.9M	-$138.5M
YoY Change	-11.25%	15.86%
Income Tax	$92.00K	$200.0K
% Of Pretax Income
Net Earnings	-$123.0M	-$138.7M
YoY Change	-11.31%	15.9%
Net Earnings / Revenue	-520.01%	-274.16%
Basic Earnings Per Share	-$0.68	-$0.78
Diluted Earnings Per Share	-$0.68	-$0.78
COMMON SHARES
Basic Shares Outstanding	181.4M shares	177.6M shares
Diluted Shares Outstanding	181.4M shares

Balance Sheet

Concept	2021 Q1	2020 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$1.037B	$1.346B
YoY Change	-22.93%	-3.08%
Cash & Equivalents	$150.2M	$227.0M
Short-Term Investments	$887.2M	$1.119B
Other Short-Term Assets	$15.77M	$13.81M
YoY Change	14.19%	-70.49%
Inventory	$16.81M	$14.32M
Prepaid Expenses
Receivables	$29.16M	$42.03M
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$1.099B	$1.429B
YoY Change	-23.11%	-4.08%
LONG-TERM ASSETS
Property, Plant & Equipment	$58.51M	$62.31M
YoY Change	-6.09%	-56.0%
Goodwill	$76.50M	$76.50M
YoY Change	0.0%
Intangibles
YoY Change
Long-Term Investments	$96.10M	$185.9M
YoY Change	-48.31%	-59.22%
Other Assets	$1.435M
YoY Change
Total Long-Term Assets	$357.5M	$458.6M
YoY Change	-22.04%	-32.2%
TOTAL ASSETS
Total Short-Term Assets	$1.099B	$1.429B
Total Long-Term Assets	$357.5M	$458.6M
Total Assets	$1.457B	$1.888B
YoY Change	-22.85%	-12.86%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$22.43M	$21.79M
YoY Change	2.96%	98.08%
Accrued Expenses	$101.2M	$97.10M
YoY Change	4.22%	25.13%
Deferred Revenue		$3.007M
YoY Change		-72.89%
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due		$254.1M
YoY Change
Total Short-Term Liabilities	$123.6M	$377.5M
YoY Change	-67.25%	278.61%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00
YoY Change		-100.0%
Other Long-Term Liabilities	$4.130M	$214.0M
YoY Change	-98.07%	15.12%
Total Long-Term Liabilities	$4.130M	$214.0M
YoY Change	-98.07%	-50.61%
TOTAL LIABILITIES
Total Short-Term Liabilities	$123.6M	$377.5M
Total Long-Term Liabilities	$4.130M	$214.0M
Total Liabilities	$462.1M	$591.5M
YoY Change	-21.89%	10.98%
SHAREHOLDERS EQUITY
Retained Earnings	-$2.432B	-$2.003B
YoY Change	21.4%
Common Stock	$3.430B	$3.307B
YoY Change	3.72%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$994.5M	$1.296B
YoY Change
Total Liabilities & Shareholders Equity	$1.457B	$1.888B
YoY Change	-22.85%	-12.86%

Cashflow Statement

Concept	2021 Q1	2020 Q1
OPERATING ACTIVITIES
Net Income	-$123.0M	-$138.7M
YoY Change	-11.31%	15.9%
Depreciation, Depletion And Amortization	$3.500M	$4.500M
YoY Change	-22.22%	45.16%
Cash From Operating Activities	-$77.09M	-$78.08M
YoY Change	-1.27%	-3.49%
INVESTING ACTIVITIES
Capital Expenditures	$2.876M	$900.0K
YoY Change	219.56%	-84.07%
Acquisitions
YoY Change
Other Investing Activities	$13.30M	$198.7M
YoY Change	-93.31%	-3156.92%
Cash From Investing Activities	$10.46M	$197.8M
YoY Change	-94.71%	-1729.32%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$17.86M	$11.08M
YoY Change	61.2%	126.34%
NET CHANGE
Cash From Operating Activities	-$77.09M	-$78.08M
Cash From Investing Activities	$10.46M	$197.8M
Cash From Financing Activities	$17.86M	$11.08M
Net Change In Cash	-$48.79M	$130.7M
YoY Change	-137.34%	-248.23%
FREE CASH FLOW
Cash From Operating Activities	-$77.09M	-$78.08M
Capital Expenditures	$2.876M	$900.0K
Free Cash Flow	-$79.96M	-$78.98M
YoY Change	1.25%	-8.74%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2021Q1	dei	Amendment Flag AmendmentFlag	false
CY2021Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2021
CY2021Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2021Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2021Q1	dei	Entity Central Index Key EntityCentralIndexKey	0000906709
CY2021Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2021Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2021Q1	dei	Document Type DocumentType	10-Q
CY2021Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2021Q1	dei	Document Period End Date DocumentPeriodEndDate	2021-03-31
CY2021Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2021Q1	dei	Entity File Number EntityFileNumber	0-24006
CY2021Q1	dei	Entity Registrant Name EntityRegistrantName	NEKTAR THERAPEUTICS
CY2021Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2021Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	94-3134940
CY2021Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	455 Mission Bay Boulevard South
CY2021Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	San Francisco
CY2021Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2021Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	94158
CY2021Q1	dei	City Area Code CityAreaCode	415
CY2021Q1	dei	Local Phone Number LocalPhoneNumber	482-5300
CY2021Q1	dei	Security12b Title Security12bTitle	Common Stock, $0.0001 par value
CY2021Q1	dei	Trading Symbol TradingSymbol	NKTR
CY2021Q1	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2021Q1	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2020Q4	nktr	Accrued Clinical Trial Expenses Current AccruedClinicalTrialExpensesCurrent	44207000	USD
CY2021Q1	nktr	Accrued Contract Manufacturing Expense Current AccruedContractManufacturingExpenseCurrent	6057000	USD
CY2020Q4	nktr	Accrued Contract Manufacturing Expense Current AccruedContractManufacturingExpenseCurrent	11310000	USD
CY2021Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	14833000	USD
CY2021Q1	dei	Entity Small Business EntitySmallBusiness	false
CY2021Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2021Q1	dei	Entity Shell Company EntityShellCompany	false
CY2021Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	182308999	shares
CY2021Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	150164000	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	198955000	USD
CY2021Q1	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	887152000	USD
CY2020Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	862941000	USD
CY2021Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	29156000	USD
CY2020Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	38889000	USD
CY2021Q1	us-gaap	Inventory Net InventoryNet	16808000	USD
CY2020Q4	us-gaap	Inventory Net InventoryNet	15292000	USD
CY2021Q1	us-gaap	Other Assets Current OtherAssetsCurrent	15771000	USD
CY2020Q4	us-gaap	Other Assets Current OtherAssetsCurrent	21928000	USD
CY2021Q1	us-gaap	Assets Current AssetsCurrent	1099051000	USD
CY2020Q4	us-gaap	Assets Current AssetsCurrent	1138005000	USD
CY2021Q1	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	96093000	USD
CY2020Q4	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	136662000	USD
CY2021Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	58510000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	59662000	USD
CY2021Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	124971000	USD
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	126476000	USD
CY2021Q1	us-gaap	Goodwill Goodwill	76501000	USD
CY2020Q4	us-gaap	Goodwill Goodwill	76501000	USD
CY2021Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1435000	USD
CY2020Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1461000	USD
CY2021Q1	us-gaap	Assets Assets	1456561000	USD
CY2020Q4	us-gaap	Assets Assets	1538767000	USD
CY2021Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	22434000	USD
CY2020Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	22139000	USD
CY2021Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	23513000	USD
CY2020Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	14532000	USD
CY2021Q1	nktr	Accrued Clinical Trial Expenses Current AccruedClinicalTrialExpensesCurrent	41028000	USD
CY2020Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	9676000	USD
CY2021Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	15768000	USD
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	13915000	USD
CY2021Q1	us-gaap	Liabilities Current LiabilitiesCurrent	123633000	USD
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	115779000	USD
CY2021Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	134556000	USD
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	136373000	USD
CY2021Q1	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	4597000	USD
CY2020Q4	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	0	USD
CY2021Q1	nktr	Liability Related To Sale Of Potential Future Royalties Non Current Net Of Issuance Costs LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts	195139000	USD
CY2020Q4	nktr	Liability Related To Sale Of Potential Future Royalties Non Current Net Of Issuance Costs LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts	200340000	USD
CY2021Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	4130000	USD
CY2020Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	8980000	USD
CY2021Q1	us-gaap	Liabilities Liabilities	462055000	USD
CY2020Q4	us-gaap	Liabilities Liabilities	461472000	USD
CY2021Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2020Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2020Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2021Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2021Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2020Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2020Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2021Q1	nktr	Preferred Stock Share Designated PreferredStockShareDesignated	0	shares
CY2021Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2020Q4	nktr	Preferred Stock Share Designated PreferredStockShareDesignated	0	shares
CY2021Q1	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2020Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2021Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2021Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2021Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	182290000	shares
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	180091000	shares
CY2021Q1	us-gaap	Common Stock Value CommonStockValue	18000	USD
CY2020Q4	us-gaap	Common Stock Value CommonStockValue	18000	USD
CY2021Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	3429734000	USD
CY2020Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	3388730000	USD
CY2021Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-3121000	USD
CY2020Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-2295000	USD
CY2021Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-2432125000	USD
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-2309158000	USD
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	994506000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	1077295000	USD
CY2021Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1456561000	USD
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1538767000	USD
CY2021Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	23647000	USD
CY2020Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	50573000	USD
CY2021Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	5756000	USD
CY2020Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	3811000	USD
CY2021Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	95604000	USD
CY2020Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	108987000	USD
CY2021Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	31679000	USD
CY2020Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	26217000	USD
CY2021Q1	nktr	Impairment Of Equipment And Other Costs For Terminated Program ImpairmentOfEquipmentAndOtherCostsForTerminatedProgram	0	USD
CY2020Q1	nktr	Impairment Of Equipment And Other Costs For Terminated Program ImpairmentOfEquipmentAndOtherCostsForTerminatedProgram	45189000	USD
CY2021Q1	us-gaap	Costs And Expenses CostsAndExpenses	133039000	USD
CY2020Q1	us-gaap	Costs And Expenses CostsAndExpenses	184204000	USD
CY2021Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-109392000	USD
CY2020Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-133631000	USD
CY2021Q1	nktr	Non Cash Interest Expense Related To Sale Of Royalties NonCashInterestExpenseRelatedToSaleOfRoyalties	13296000	USD
CY2020Q1	nktr	Non Cash Interest Expense Related To Sale Of Royalties NonCashInterestExpenseRelatedToSaleOfRoyalties	6968000	USD
CY2021Q1	us-gaap	Liabilities Fair Value Adjustment LiabilitiesFairValueAdjustment	-1599000	USD
CY2020Q1	us-gaap	Liabilities Fair Value Adjustment LiabilitiesFairValueAdjustment	0	USD
CY2021Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	1412000	USD
CY2020Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	8352000	USD
CY2021Q1	us-gaap	Interest Expense InterestExpense	0	USD
CY2020Q1	us-gaap	Interest Expense InterestExpense	6204000	USD
CY2021Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-13483000	USD
CY2020Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-4820000	USD
CY2021Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-122875000	USD
CY2020Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-138451000	USD
CY2021Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	92000	USD
CY2020Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	200000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-122967000	USD
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-138651000	USD
CY2021Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.68
CY2020Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.78
CY2021Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	181370000	shares
CY2020Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	177185000	shares
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-122967000	USD
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-138651000	USD
CY2021Q1	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-766000	USD
CY2020Q1	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-5121000	USD
CY2021Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-60000	USD
CY2020Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-751000	USD
CY2021Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-826000	USD
CY2020Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-5872000	USD
CY2021Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-123793000	USD
CY2020Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-144523000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	1405391000	USD
CY2020Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	11347000	USD
CY2020Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	24211000	USD
CY2020Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-144523000	USD
CY2020Q1	us-gaap	Stockholders Equity StockholdersEquity	1296426000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	1077295000	USD
CY2021Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	17106000	USD
CY2021Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	23898000	USD
CY2021Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-123793000	USD
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	994506000	USD
CY2021Q1	us-gaap	Profit Loss ProfitLoss	-122967000	USD
CY2020Q1	us-gaap	Profit Loss ProfitLoss	-138651000	USD
CY2021Q1	nktr	Non Cash Royalty Revenue Related To Sale Of Future Royalties NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties	18798000	USD
CY2020Q1	nktr	Non Cash Royalty Revenue Related To Sale Of Future Royalties NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties	9895000	USD
CY2021Q1	nktr	Non Cash Interest Expense Related To Sale Of Royalties NonCashInterestExpenseRelatedToSaleOfRoyalties	13296000	USD
CY2020Q1	nktr	Non Cash Interest Expense Related To Sale Of Royalties NonCashInterestExpenseRelatedToSaleOfRoyalties	6968000	USD
CY2021Q1	us-gaap	Liabilities Fair Value Adjustment LiabilitiesFairValueAdjustment	-1599000	USD
CY2020Q1	us-gaap	Liabilities Fair Value Adjustment LiabilitiesFairValueAdjustment	0	USD
CY2021Q1	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	2248000	USD
CY2020Q1	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	0	USD
CY2021Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	23898000	USD
CY2020Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	25236000	USD
CY2021Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	3543000	USD
CY2020Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	4502000	USD
CY2021Q1	nktr	Impairment Of Equipment From Terminated Program ImpairmentOfEquipmentFromTerminatedProgram	0	USD
CY2020Q1	nktr	Impairment Of Equipment From Terminated Program ImpairmentOfEquipmentFromTerminatedProgram	20351000	USD
CY2021Q1	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-2345000	USD
CY2020Q1	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	1289000	USD
CY2021Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-9733000	USD
CY2020Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	5229000	USD
CY2021Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1516000	USD
CY2020Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1655000	USD
CY2021Q1	nktr	Increase Decrease In Operating Lease Right Of Use Assets Net Of Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities	-1541000	USD
CY2020Q1	nktr	Increase Decrease In Operating Lease Right Of Use Assets Net Of Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities	-2940000	USD
CY2021Q1	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-6183000	USD
CY2020Q1	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-1067000	USD
CY2021Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	779000	USD
CY2020Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	2687000	USD
CY2021Q1	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	8981000	USD
CY2020Q1	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	9920000	USD
CY2021Q1	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	-7345000	USD
CY2020Q1	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	7483000	USD
CY2021Q1	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-605000	USD
CY2020Q1	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-2510000	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-77085000	USD
CY2020Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-78075000	USD
CY2021Q1	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	295314000	USD
CY2020Q1	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	241068000	USD
CY2021Q1	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	303612000	USD
CY2020Q1	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	439735000	USD
CY2021Q1	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	5036000	USD
CY2020Q1	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	0	USD
CY2021Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	2876000	USD
CY2020Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	900000	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	10458000	USD
CY2020Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	197767000	USD
CY2021Q1	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans	17106000	USD
CY2020Q1	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans	11077000	USD
CY2021Q1	us-gaap	Proceeds From Derivative Instrument Financing Activities ProceedsFromDerivativeInstrumentFinancingActivities	750000	USD
CY2020Q1	us-gaap	Proceeds From Derivative Instrument Financing Activities ProceedsFromDerivativeInstrumentFinancingActivities	0	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	17856000	USD
CY2020Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	11077000	USD
CY2021Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-20000	USD
CY2020Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-97000	USD
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-48791000	USD
CY2020Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	130672000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	198955000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	96363000	USD
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	150164000	USD
CY2020Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	227035000	USD
CY2021Q1	us-gaap	Interest Paid Net InterestPaidNet	0	USD
CY2020Q1	us-gaap	Interest Paid Net InterestPaidNet	4951000	USD
CY2021Q1	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	1057000	USD
CY2020Q1	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	2133000	USD
CY2021Q1	nktr	Cash Restricted Cash Cash Equivalents And Available For Sale Investments CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments	1100000000	USD
CY2021Q1	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Accounting estimates and assumptions are inherently uncertain. </span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Actual results could differ materially from those estimates and assumptions. As appropriate, we assess our estimates each period, update them to reflect current information and generally recognize any changes in such estimates in the period first identified.</span></div>
CY2021Q1	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reclassifications</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain items previously reported in specific financial statement captions have been reclassified to conform to the current period presentation. Such reclassifications do not materially impact previously reported revenue, operating loss, net loss, total assets, liabilities or stockholders’ equity.</span></div>
CY2021Q1	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2021Q1	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2021Q1	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Significant Concentrations</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our customers are primarily pharmaceutical and biotechnology companies that are located in the U.S. and Europe and with whom we have multi-year arrangements. Our accounts receivable balance contains billed and unbilled trade receivables from product sales, milestones (to the extent that they have been achieved and are due from the counterparty), and other contingent payments, as well as reimbursable costs from collaborative research and development agreements. As of March 31, 2021, our accounts receivable includes $26.2 million for unbilled net expense reimbursements from our collaboration partner Bristol-Myers Squibb Company (BMS) and $2.9 million under customer contracts from our collaboration partners. As of December 31, 2020, our accounts receivable included $38.7 million for unbilled net expense reimbursements from BMS and $0.2 million from customer contracts. We generally do not require collateral from our customers. We perform a regular review of our customers’ credit risk and payment histories, including payments made after period end. Historically, we have not experienced credit losses from our accounts receivable and recorded no bad debt expense for the three months ended March 31, 2021 and 2020. We have not recorded a reserve for credit losses at March 31, 2021 or December 31, 2020.</span></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are dependent on our suppliers and contract manufacturers to provide raw materials and drugs of appropriate quality and reliability and to meet applicable contract and regulatory requirements. In certain cases, we rely on single sources of supply of one or more critical materials. Consequently, in the event that supplies are delayed or interrupted for any reason, including as a result of the COVID-19 pandemic, our ability to develop and produce our drug candidates, our ability to supply comparator drugs for our clinical trials, or our ability to meet our supply obligations could be significantly impaired, which could have a material adverse effect on our business, financial condition and results of operations.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For our available-for-sale securities, we have significant concentrations of issuers in the banking and financial services industry. While our investment policy requires that we only invest in highly-rated securities and limit our exposure to any single issuer, a deterioration in this industry could have a material effect on our results of operations and financial position. Additionally, pursuant to our investment policy, we may sell securities before maturity if the issuer’s credit rating has been downgraded below our minimum credit rating requirements, which may result in a loss on the sale. Accordingly, if factors, including the effects of the COVID-19 pandemic, result in downgrades below our minimum credit rating requirements and if we decide to sell these securities, we may experience losses on such sales.</span></div>
CY2021Q1	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	0	USD
CY2020Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	0	USD
CY2021Q1	nktr	Sale Of Stock Value Authorized In Transaction SaleOfStockValueAuthorizedInTransaction	300000000.0	USD
CY2021Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	150164000	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	198955000	USD
CY2021Q1	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	887152000	USD
CY2020Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	862941000	USD
CY2021Q1	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	96093000	USD
CY2020Q4	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	136662000	USD
CY2021Q1	nktr	Cash Restricted Cash Cash Equivalents And Available For Sale Investments CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments	1133409000	USD
CY2020Q4	nktr	Cash Restricted Cash Cash Equivalents And Available For Sale Investments CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments	1198558000	USD
CY2021Q1	nktr	Debt Investment Maximum Maturity Period DebtInvestmentMaximumMaturityPeriod	P2Y
CY2021Q1	nktr	Debt Investment Maturity Term DebtInvestmentMaturityTerm	P1Y
CY2021Q1	us-gaap	Cash Cash	7559000	USD
CY2020Q4	us-gaap	Cash Cash	6285000	USD
CY2021Q1	nktr	Cash Restricted Cash Cash Equivalents And Available For Sale Investments CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments	1133409000	USD
CY2020Q4	nktr	Cash Restricted Cash Cash Equivalents And Available For Sale Investments CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments	1198558000	USD
CY2020Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	1100000	USD
CY2020Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	200000	USD
CY2021Q1	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	1920000	USD
CY2020Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	2422000	USD
CY2021Q1	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	13082000	USD
CY2020Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	10703000	USD
CY2021Q1	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	1806000	USD
CY2020Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	2167000	USD
CY2021Q1	us-gaap	Inventory Net InventoryNet	16808000	USD
CY2020Q4	us-gaap	Inventory Net InventoryNet	15292000	USD
CY2021Q1	nktr	License Collaboration Other Revenue LicenseCollaborationOtherRevenue	54000	USD
CY2020Q1	nktr	License Collaboration Other Revenue LicenseCollaborationOtherRevenue	27515000	USD
CY2021Q1	us-gaap	Contract With Customer Performance Obligation Satisfied In Previous Period ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod	18800000	USD
CY2020Q1	us-gaap	Contract With Customer Performance Obligation Satisfied In Previous Period ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod	44600000	USD
CY2021Q1	nktr	Potential Development And Regulatory Milestones PotentialDevelopmentAndRegulatoryMilestones	1700000000	USD
CY2021Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	23898000	USD
CY2020Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	25236000	USD
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	121000	shares
CY2020Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	49000	shares
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	10.82
CY2020Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	11.88
CY2021Q1	us-gaap	Stock Issued During Period Shares Share Based Compensation StockIssuedDuringPeriodSharesShareBasedCompensation	2199000	shares
CY2020Q1	us-gaap	Stock Issued During Period Shares Share Based Compensation StockIssuedDuringPeriodSharesShareBasedCompensation	1358000	shares
CY2021Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	19393000	shares
CY2020Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	18816000	shares

Files In Submission

Name	View Source	Status
0000906709-21-000008-index-headers.html	Edgar Link	pending
0000906709-21-000008-index.html	Edgar Link	pending
0000906709-21-000008.txt	Edgar Link	pending
0000906709-21-000008-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
nktr-20210331.htm	Edgar Link	pending
nktr-20210331.xsd	Edgar Link	pending
nktr-20210331_cal.xml	Edgar Link	unprocessable
nktr-20210331_def.xml	Edgar Link	unprocessable
nktr-20210331_htm.xml	Edgar Link	completed
nktr-20210331_lab.xml	Edgar Link	unprocessable
nktr-20210331_pre.xml	Edgar Link	unprocessable
nktr2021-03x31xexx311.htm	Edgar Link	pending
nktr2021-03x31xexx312.htm	Edgar Link	pending
nktr2021-03x31xexx321.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$NKTR
NEKTAR THERAPEUTICS Stock $nktr

2021 Q1 Form 10-Q Financial Statement

#000090670921000008 Filed on May 07, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NKTR NEKTAR THERAPEUTICS Stock $nktr

2021 Q1 Form 10-Q Financial Statement

#000090670921000008 Filed on May 07, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NKTR
NEKTAR THERAPEUTICS Stock $nktr